Risk of Seizures Associated with the Use of Antibiotics from the Cephalosporin Group

Article Sidebar

PDF
Published: Sep 26, 2024
Keywords:
pharmacovigilance risk minimization adverse drug reaction cephalosporins seizures

Main Article Content

Alejandro E. Svarch
Titular de la Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS)
Miriam Jackeline Loera-Rosales
Commissioner for Evidence and Risk Management
Diana Edith Sánchez-Arceo
Directora Ejecutiva de Farmacopea y Farmacovigilancia, COFEPRIS
Rogelio Ríos-Quintana
Comisión de Evidencia y Manejo de Riesgos-COFEPRIS
Mayte Guadalupe Cervantes-Badillo
Researcher for Mexico, Conahcyt

Abstract

Mexico is a member of the “International Program for Monitoring Adverse Drug Reactions” of the World Health Organization and, through the National Pharmacovigilance Center, it promotes actions regarding drug safety that contribute to the well-being of patients and their rational use. The evaluation of the safety profile of cephalosporins marketed in Mexico allowed us to identify that the risk of seizures and predisposing factors were not described in the prescribing information of some of them, so COFEPRIS implemented a series of measures to minimize this risk.

Article Details

How to Cite
Svarch, Alejandro E., Miriam Jackeline Loera-Rosales, Diana Edith Sánchez-Arceo, Rogelio Ríos-Quintana, and Mayte Guadalupe Cervantes-Badillo. 2024. “Risk of Seizures Associated With the Use of Antibiotics from the Cephalosporin Group”. Revista Mexicana De Política Exterior, no. 129 (September):87-98. https://revistadigital.sre.gob.mx/index.php/rmpe/article/view/2687.
Issue
No. 129 (2024): Regulatory Diplomacy in Latin America and the Caribbean
Section
Articles

Most read articles by the same author(s)